Dr Alberto Lledó has joined Canbex Therapeutics as chief medical officer.
Dr Lledó is currently a senior consultant neurologist at Clínica Creu Blanca in Barcelona, Spain, although has pharma experience that includes 16 years at Lilly from 1995 to 2011.
During his time at Lilly he served in several senior positions, including global senior medical adviser and CNS clinical research physician for Europe, and helped co-ordinate phase II clinical trials for the company’s neurology pipeline.
As chief medical officer at Canbex Dr Lledó will lead preparations for proof of concept trials for the company’s lead candidate VSN16R, an oral drug intended for the treatment of spasticity in people with multiple sclerosis.
“I am delighted to be joining Canbex at such an important time in the development of VSN16R,” Dr Lledó said. “As a practicing neurologist and experienced drug developer, I am very pleased to be addressing a serious need among people with multiple sclerosis for improved treatment of their spasticity.”